Compare RVSB & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | ALDX |
|---|---|---|
| Founded | 1923 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 88.1M |
| IPO Year | 1997 | 2014 |
| Metric | RVSB | ALDX |
|---|---|---|
| Price | $5.78 | $1.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $7.00 | $5.50 |
| AVG Volume (30 Days) | 47.7K | ★ 637.5K |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $71.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.81 | $1.07 |
| 52 Week High | $6.22 | $5.93 |
| Indicator | RVSB | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 75.87 | 40.90 |
| Support Level | $5.23 | $1.07 |
| Resistance Level | $5.84 | $1.58 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 95.16 | 23.91 |
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment services. It has single operating segment.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.